Boston Scientific Corporation (BSX) Free Cash Flow CAGR:19.81%(TTM)
Free cash flow CAGR uses precomputed cash-flow statement history.
Over longer horizons, Boston Scientific Corporation's Free Cash Flow CAGR averages 43.03% over 3 years and 19.89% over 5 years.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. Free cash flow CAGR measures how Boston Scientific Corporation's cash generation has grown. FCF represents the cash available for dividends, buybacks, debt reduction, or reinvestment.
BSX Free Cash Flow CAGR Chart
Boston Scientific Corporation (BSX)
BSX Quarterly Free Cash Flow Growth (YoY)
Free Cash Flow growth vs the same quarter one year earlier, last 20 quarters.
BSX Free Cash Flow CAGR History
| Year | Start FCF | End FCF | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | $2.65B | $3.66B | +$1.01B | +38.30% | +38.30% |
| 2024 | $1.70B | $2.65B | +$942.00M | +55.31% | +55.31% |
| 2023 | $914.00M | $1.70B | +$789.00M | +86.32% | +86.32% |
| 2022 | $1.32B | $914.00M | $-402.00M | -30.55% | -30.55% |
| 2021 | $1.13B | $1.32B | +$184.00M | +16.25% | +16.25% |
| 2020 | $1.38B | $1.13B | $-243.00M | -17.67% | -17.67% |
| 2019 | $-6.00M | $1.38B | +$1.38B | N/A | N/A |
| 2018 | $1.11B | $-6.00M | $-1.11B | -100.54% | N/A |
| 2017 | $596.00M | $1.11B | +$511.00M | +85.74% | +85.74% |
| 2016 | $353.00M | $596.00M | +$243.00M | +68.84% | +68.84% |
| 2015 | $1.01B | $353.00M | $-657.00M | -65.05% | -65.05% |
| 2014 | $837.00M | $1.01B | +$173.00M | +20.67% | +20.67% |
| 2013 | $1.03B | $837.00M | $-197.00M | -19.05% | -19.05% |
| 2012 | $704.00M | $1.03B | +$330.00M | +46.88% | +46.88% |
| 2011 | $47.00M | $704.00M | +$657.00M | +1397.87% | +1397.87% |
| 2010 | $473.00M | $47.00M | $-426.00M | -90.06% | -90.06% |
| 2009 | $854.00M | $473.00M | $-381.00M | -44.61% | -44.61% |
| 2008 | $571.00M | $854.00M | +$283.00M | +49.56% | +49.56% |
| 2007 | $1.50B | $571.00M | $-933.00M | -62.03% | -62.03% |
| 2006 | $562.00M | $1.50B | +$942.00M | +167.62% | +167.62% |
| 2005 | $1.53B | $562.00M | $-968.00M | -63.27% | -63.27% |
| 2004 | $599.00M | $1.53B | +$931.00M | +155.43% | +155.43% |
| 2003 | $624.00M | $599.00M | $-25.00M | -4.01% | -4.01% |
| 2002 | $369.00M | $624.00M | +$255.00M | +69.11% | +69.11% |
| 2001 | $663.00M | $369.00M | $-294.00M | -44.34% | -44.34% |
| 2000 | $647.00M | $663.00M | +$16.00M | +2.47% | +2.47% |
| 1999 | $-1.98B | $647.00M | +$2.62B | N/A | N/A |
| 1998 | $-157.70M | $-1.98B | $-1.82B | N/A | N/A |
| 1997 | $-1.00M | $-157.70M | $-156.70M | N/A | N/A |
Quarterly Free Cash Flow: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q1 2026 | $171.00M | -83.1% | -51.7% |
| Q4 2025 | $1.01B | -12.8% | -12.9% |
| Q3 2025 | $1.16B | +6.0% | +66.5% |
| Q2 2025 | $1.10B | +209.6% | +66.6% |
| Q1 2025 | $354.00M | -69.6% | — |
| Q4 2024 | $1.16B | +66.6% | +68.6% |
| Q3 2024 | $698.00M | +6.1% | +41.9% |
| Q2 2024 | $658.00M | — | +45.6% |
| Q1 2024 | -$81.00M | — | — |
| Q4 2023 | $690.00M | +40.2% | +13.7% |
| Q3 2023 | $492.00M | +8.8% | +65.1% |
| Q2 2023 | $452.00M | +555.1% | +123.8% |
| Q1 2023 | $69.00M | -88.6% | — |
| Q4 2022 | $607.00M | +103.7% | +186.3% |
| Q3 2022 | $298.00M | +47.5% | -16.8% |
| Q2 2022 | $202.00M | — | -62.4% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About Boston Scientific Corporation
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Michael F. Mahoney